Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.42 |
| ▸ | CD69 | Q07108 | 1/20 | 0.42 |
| ▸ | SLC28A3 | Q9HAS3 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27921424 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| SCHEMBL8648898 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| SCHEMBL460988 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| SCHEMBL7094225 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| SCHEMBL2413753 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| SCHEMBL25166887 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| SCHEMBL1898656 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| SCHEMBL181028 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| Hydrochloric Acid SCHEMBL28256651 | 0.98 | LMNA (0.42) | LMNAKDM4EALOX15LGALS8CD69 | |
| Ammonia Solution, Strong SCHEMBL27636528 | 0.98 | LMNA (0.42) | LMNAKDM4EALOX15LGALS8CD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120943928-B | Human calcitonin modification method, modified human calcitonin and application thereof | 井冈山大学 | 2026-05-15 | — | — | CN | claimed |
| US-20260097055-A1 | COGNITION | CULLIS HILL SYDNEY DAVID (AU) | 2026-04-09 | — | — | US | claimed |
| US-12521409-B2 | Cognition | CULLIS HILL SYDNEY DAVID (AU) | 2026-01-13 | — | — | US | claimed |
| WO-2024010609-A1 | PRISTINE GRAPHENE BASED BIOSENSOR FOR BIOMARKER DETECTION AND RELATED CORE PARTICLES, MATERIALS COMPOSITIONS METHODS AND SYSTEMS | HAWKEYE BIO, LIMITED (IE) | 2024-01-11 | — | — | WO | claimed |
| CN-106459259-B | N-acetylglucosaminyl sugar chain group-containing compound, carrier compound for drug delivery, preparation, and drug delivery system | 索马龙株式会社 | 2022-07-15 | — | — | CN | claimed |
| CN-110609078-B | Method for detecting protein phosphorylation and acetylglucosamine saccharification correlation effect | 南京谱利健生物技术有限公司 | 2022-03-11 | — | — | CN | claimed |
| CN-109072482-A | MULTIVALENT GLYCAN MICROARRAY PLATFORM | Z生物科技有限公司 | 2018-12-21 | — | — | CN | claimed |
| CN-106413737-A | Composition for preventing or treating staphylococcus aureus infection | 株式会社绿十字 | 2017-02-15 | — | — | CN | claimed |
| CN-120943928-B | Human calcitonin modification method, modified human calcitonin and application thereof | 井冈山大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-120943928-B | Human calcitonin modification method, modified human calcitonin and application thereof | 井冈山大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20260035422-A1 | FOLLISTATIN-LIKE 1 (FSTL1) FOR REPAIRING CARDIAC TISSUE | REGENCOR INC (US) | 2026-02-05 | — | — | US | disclosed |
| CN-120943928-A | Human calcitonin modification method, modified human calcitonin and application thereof | 井冈山大学 | 2025-11-14 | — | — | CN | disclosed |
| CN-120118997-A | MiRNA marker for diagnosing and treating colorectal cancer and application of miRNA marker in preparation of medicines for preventing and treating colorectal cancer | 宿州学院 | 2025-06-10 | — | — | CN | disclosed |
| CN-118662495-A | Application of DON in preparation of medicine for treating cerebral ischemia injury | 南通市妇幼保健院 | 2024-09-20 | — | — | CN | disclosed |
| CN-105142399-A | Biocompatible and bioabsorbable derivatized chitosan compositions | HEMCON MEDICAL TECHNOLOGIES INC | 2015-12-09 | — | — | CN | disclosed |
| CN-104327128-A | Preparation method of glucosamine hydrochloride | CHONGQING DAXIN PHARMACEUTICAL CO LTD | 2015-02-04 | — | — | CN | disclosed |
| CN-104169411-A | Water soluble compositions incorporating enzymes, and method of making same | MONOSOL LLC | 2014-11-26 | — | — | CN | disclosed |
| CN-102686216-A | Highly concentrated pharmaceutical formulations comprising anti-CD 20 antibodies | HOFFMANN LA ROCHE | 2012-09-19 | — | — | CN | disclosed |
| CN-101735337-A | Method for preparing chitin and chitosan | CHINESE ACAD INST MICROBIOLOGY | 2010-06-16 | — | — | CN | disclosed |
| CN-85107911-A | The production method of ellipticine derivative | — | 1987-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035422-A1 | FOLLISTATIN-LIKE 1 (FSTL1) FOR REPAIRING CARDIAC TISSUE | ACVRL1, FN1, FNIP1 | LMNA 1443/4885KDM4E 2652/4885ALOX15 4510/4885 |
| US-20260097055-A1 | COGNITION | FUT5, GLA, CSGALNACT1 | LMNA 4192/4885KDM4E 2501/4885ALOX15 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.